临床试验/NCT07072299

NCT07072299尚未招募不适用

DEB-BACE for Primary Lung Cancer: A Retrospective, Single-Arm, Multicenter Study on Efficacy and Safety

Gang Wu, MD0 个研究点目标入组 1,213 人开始时间: 2025年8月1日最近更新: 2025年7月18日

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 1,213
主要终点: ORR

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

This is a retrospective, single-arm, multicenter clinical study designed to evaluate the efficacy and safety of DEB-BACE (Drug-Eluting Bead Bronchial Artery Chemoembolization) in the treatment of primary lung cancer.

研究设计

研究类型: Observational
观察模型: Other
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age ≥ 18 years old, gender unrestricted;
•Diagnosed with primary lung cancer based on the Primary Lung Cancer Diagnosis and Treatment Guidelines (2022 Edition) through histopathological examination;
•At least one measurable lesion (evaluated according to RECIST 1.1 criteria);
•Previously received at least one DEB-BACE treatment;
•ECOG PS score ≤ 2;
•Complete patient case records.

排除标准

•Presence of extensive and uncontrolled extrapulmonary brain metastasis lesions;
•Irreversible coagulation dysfunction within a short period of time;
•Uncontrollable hypertension, diabetes, or significant cardiovascular diseases with obvious symptoms;
•Allergy to contrast agent;
•Pregnant or lactating women;
•Patients whose condition, as judged by the investigator, poses a serious threat to patient safety or hinders their participation in the study.

结局指标

主要结局

ORR

时间窗: up to 1 years

ORR is defined as the percentages of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to mRECIST 1.1 criteria

次要结局

PFS(up to 1 years)
OS(up to1 years)

研究者

发起方

Gang Wu, MD

申办方类型

Other

责任方

Sponsor Investigator

主要研究者

Gang Wu, MD

The First Affiliated Hospital of Zhengzhou University

相似试验

尚未招募

不适用

Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment FailureCarcinoma, Non-Small-Cell Lung

NCT05248022The Central Hospital of Lishui City98

尚未招募

不适用

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLCCarcinomaSmall Cell Lung Cancer

NCT06364046The Central Hospital of Lishui City56

招募中

不适用

A Clinico-biological Database of Lung CancersLung Cancer

NCT03387865University Hospital, Lille500

尚未招募

2 期

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line ImmunotherapyNon-small Cell Lung Cancer

NCT06182800The First Affiliated Hospital of Xinxiang Medical College35

招募中

2 期

Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal CancerRectal CancerAdvanced Stage Colorectal CancerRadiotherapy

NCT06765616Feng Tian31